|Articles|October 26, 2012
Pharmaceutical Company to Pay $95M to Settle Allegations of Improper Drug Promotion
Advertisement
Boehringer Ingelheim Pharmaceuticals Inc. will pay $95 million to settle allegations that the company promoted three drugs for uses that were not medically accepted, the government announced Thursday.
The Justice Department said the three are the stroke-prevention drug Aggrenox, the chronic obstructive pulmonary disease drug Combivent and the high-blood-pressure drug Micardis.
Read the full story:
Source: The Washington Post
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA to Restrict Ingredients Used in Mass-Marketed Compounded GLP-1s, Crack Down on Misleading Ads
2
Contributor: Reimagining Beneficiary Engagement in Accountable Care Models to Make America Healthy Again
3
5 Things to Know About the Oral GLP-1 Era
4
Overcoming Mistrust in Clinical Trial Enrollment Through Community Resources: Susan Vadaparampil, PhD, MPH
5
